Trial Profile
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Serelaxin (Primary)
- Indications Preeclampsia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis
- 14 Jul 2014 Planned End Date changed from 1 Apr 2017 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 14 Jul 2014 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 14 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.